cemiplimab


( Last Updated : October 7, 2021)
Generic Name:
cemiplimab
Project Status:
Active
Therapeutic Area:
Basal cell carcinoma
Manufacturer:
Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Brand Name:
Libtayo
Project Line:
Reimbursement Review
Project Number:
PC0260-000
Tumour Type:
Skin & Melanoma
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open 21-Jul-21
Call for patient/clinician input closed 13-Sep-21
Clarification:

- Patient input submission received from Melanoma Network of Canada and Save Your Skin Foundation

Submission received 19-Aug-21
Submission accepted 02-Sep-21
Review initiated 03-Sep-21
Draft CADTH review report(s) provided to sponsor for comment 18-Nov-21
Deadline for sponsors comments 29-Nov-21
CADTH review report(s) and responses to comments provided to sponsor 23-Dec-21
Expert committee meeting (initial) 12-Jan-22
Draft recommendation issued to sponsor January 24, 2022
To
January 26, 2022
Draft recommendation posted for stakeholder feedback  
End of feedback period